Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis Over 48 Weeks: A Randomized, Placebo-Controlled, Phase 2 Study

Xavier Montalban, Douglas L Arnold, Martin S Weber, Ivan Staikov, Karolina Piasecka-Stryczynska, Emily C Martin, Sana Syed, Fernando Dangond, Jerry S Wolinsky